Europe Oral Anti-Diabetic Drug - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The europe oral anti-diabetic drug market size was valued at USD 7.61 billion in 2025 and estimated to grow from USD 7.86 billion in 2026 to reach USD 9.2 billion by 2031, at a CAGR of 3.22% during the forecast period (2026-2031). This report is Segmented by Drug Class (Biguanides, Sulfonylureas, Meglitinides, and More), Age Group (Adults, Pediatric, Geriatric), Diabetes Type (Type 1 Diabetes, Type 2 Diabetes), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography (Germany, United Kingdom, France, Italy, and More). The Market Forecasts are Provided in Terms of Value (USD).

Europe Oral Anti-Diabetic Drug Market Trends and Insights

Escalating Prevalence of Type-2 Diabetes & Obesity

Population ageing and lifestyle changes keep the absolute number of diabetic adults climbing despite public-health efforts. The International Diabetes Federation projects 784 million global cases by 2045, a figure that underpins long-run volume growth for every therapeutic class. Recent Italian market data showed annual GLP-1 spending of EUR 26 billion in 2024, with private out-of-pocket purchases doubling as patients pursue advanced options. Similar momentum appeared in Portugal where sales neared EUR 20 million in early 2025 even without reimbursement. Spain’s weight-management segment rose 65% to EUR 484 million in 2024, underscoring unmet demand that transcends traditional payer funding. Collectively, these country snapshots illustrate how obesity trends directly expand the Europe oral anti-diabetic drug market.

EU-Wide Cardio-Renal Label Expansions for the SGLT-2 Class

The European Commission’s 2024 approval of empagliflozin (Jardiance) for chronic kidney disease reframed SGLT-2 inhibitors as cardio-metabolic agents rather than glucose-lowering drugs alone. With an estimated 47 million Europeans living with CKD, the addressable pool widened materially. Jardiance generated EUR 7.4 billion in 2023 revenue, reflecting 31% annual growth. Meta-analyses confirm superior reductions in HbA1c, BMI and systolic blood pressure relative to DPP-4 inhibitors, while also cutting hospitalisation for heart failure. These multidimensional benefits strengthen clinician confidence and elevate the Europe oral anti-diabetic drug market growth path.

High List Prices of Novel Incretin & SGLT-2 Therapies

Annual acquisition costs for GLP-1 agents can exceed USD 16,000, challenging public budgets already stretched by multiple sclerosis, oncology and rare-disease drugs. Germany excludes weight-loss indications from statutory reimbursement, while France removed Wegovy from its positive list in late 2023 following incremental-benefit review. The United Kingdom limits access to specialist obesity clinics pending full NICE roll-out. Although cardiovascular-outcomes evidence continues to accumulate, payer hesitancy persists. Roughly 76 million obese but non-diabetic adults across the EU-5 therefore remain priced out of therapy, constraining upside for the Europe oral anti-diabetic drug market.

Other drivers and restraints analyzed in the detailed report include:

• Uptake of Oral GLP-1 (Semaglutide/Rybelsus)
• E-Prescription Mandates Accelerating E-Pharmacy Channels
• Safety Signals: SGLT-2-Induced Euglycaemic DKA Cases

Segment Analysis

Biguanides continued to command 38.05% of 2025 prescriptions, anchoring first-line therapy due to low cost and extensive familiarity. However, SGLT-2 inhibitors delivered the fastest 3.72% CAGR toward 2031 as multidimensional cardio-renal benefits drive physician preference. Sulfonylurea use declined sharply in parts of Southern Europe, mirroring global de-adoption trends linked to hypoglycaemia risk. DPP-4 inhibitors maintained a steady but unremarkable footprint, chiefly in patients unsuitable for SGLT-2 or GLP-1 agents.

The “others” bucket, including dual GIP/GLP-1 agonists such as tirzepatide, shows high clinical promise following network meta-analyses that reported a 2.24% HbA1c decline. Alpha-glucosidase inhibitors and thiazolidinediones now occupy niche roles, reserved for specific intolerance scenarios. Across this landscape, the Europe oral anti-diabetic drug market size allotted to innovation-driven classes keeps expanding, even as metformin retains volume leadership. Declining sulfonylurea demand exemplifies how guideline shifts and outcome data continuously reshape the Europe oral anti-diabetic drug market.

Adults accounted for 66.35% of 2025 utilisation, reflecting the core working-age burden of type 2 diabetes. Yet the geriatric segment exhibited a 3.86% CAGR, powered by refined guidelines that advocate complication-oriented treatment regardless of chronological age. Swiss registry data highlight persistently sub-optimal control rates among seniors, underscoring the need for agents with low hypoglycaemia risk. SGLT-2 inhibitors and GLP-1 receptor agonists meet that requirement but necessitate vigilant renal-function monitoring.

Portuguese community studies revealed 97.7% adherence in older adults yet low achievement of blood-pressure and fasting-glucose targets, signalling unmet multidimensional needs. Digital therapeutics show promise: AI-driven “digital twin” models cut medication requirements by 74% while preserving glycaemia. These trends collectively elevate the Europe oral anti-diabetic drug market size associated with the geriatric cohort. Paediatric prescriptions remain modest, limited chiefly to metformin in adolescents experiencing insulin resistance.

Complete Report Scope:

• By Drug Class
  • Biguanides
  • Sulfonylureas
  • Meglitinides
  • Thiazolidinediones
  • Alpha-Glucosidase Inhibitors
  • DPP-4 Inhibitors
  • SGLT-2 Inhibitors
  • Others
• By Age Group
  • Adults
  • Pediatric
  • Geriatric
• By Diabetes Type
  • Type 1 Diabetes
  • Type 2 Diabetes
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Geography
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Rest of Europe

List of Companies Covered in this Report:

• Novo Nordisk
• Eli Lilly and Company
• Boehringer Ingelheim
• AstraZeneca
• Johnson & Johnson
• Merck
• Sanofi
• Takeda Pharmaceuticals
• Pfizer
• Bristol-Myers Squibb
• Astellas Pharma
• Novartis
• Teva Pharmaceutical Industries
• Viatris
• Sun Pharmaceuticals Industries
• Recordati
• Servier
• Lupin
• Zentiva

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support